Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Aozora Corporate Investment-backed Japan Next Generation fund invests in Coalis Capital’s Coalis Fund I

Aozora Corporate Investment-backed Japan Next Generation fund invests in Coalis Capital’s Coalis Fund I

ReutersReuters2026/09/15 02:17
  • Aozora Corporate Investment backed Coalis Capital’s Coalis No. 1 investment limited partnership via the Japan Next Generation fund.
  • Coalis Capital runs a growth buyout fund targeting majority stakes in Japan growth-stage startups, mainly in internet, software.
  • The strategy centers on control investments with hands-on operational support to drive value creation, including M&A, PMI, governance buildout.
  • Coalis Capital was established on Feb. 20, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aozora Corporate Investment Co Ltd published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma